BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33126591)

  • 1. Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC.
    Cao J; Zhao W; Zhao C; Liu Q; Li S; Zhang G; Chou CJ; Zhang Y
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33126591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer.
    Jia G; Qi K; Hou B; Yue K; Xu T; Jiang Y; Li X
    Eur J Med Chem; 2023 Nov; 260():115752. PubMed ID: 37647727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
    Tashima T; Murata H; Kodama H
    Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin.
    Gao JJ; Gao ZH; Zhao CR; Yuan Y; Cui SX; Zhang XF; Cheng YN; Xu WF; Tang W; Qu XJ
    Invest New Drugs; 2011 Aug; 29(4):574-82. PubMed ID: 20111888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8.
    Sun Z; Deng B; Yang Z; Mai R; Huang J; Ma Z; Chen T; Chen J
    Eur J Med Chem; 2022 Sep; 239():114544. PubMed ID: 35759908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing HDAC-PROTACs: lessons learned so far.
    Fischer F; Alves Avelar LA; Murray L; Kurz T
    Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LYP3, a new bestatin derivative for aminopeptidase N inhibition.
    Luan Y; Ma C; Sui Z; Wang X; Feng J; Liu N; Jing F; Wang Y; Li M; Fang H; Xu W
    Med Chem; 2011 Jan; 7(1):32-6. PubMed ID: 21235517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.
    Shahidul Islam M; Nurul Islam M; Ashraful Hoque M; Nishino N; Kato T; Kim HJ; Ito A; Yoshida M
    Bioorg Chem; 2015 Apr; 59():145-50. PubMed ID: 25797804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
    Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI
    Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
    Negmeldin AT; Padige G; Bieliauskas AV; Pflum MK
    ACS Med Chem Lett; 2017 Mar; 8(3):281-286. PubMed ID: 28337317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands.
    Lu Y; Sun D; Xiao D; Shao Y; Su M; Zhou Y; Li J; Zhu S; Lu W
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
    Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
    Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
    Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
    Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of bestatin in the retina of streptozotocin-induced diabetic mice.
    Hossain A; Heron D; Davenport I; Huckaba T; Graves R; Mandal T; Muniruzzaman S; Wang S; Bhattacharjee PS
    Exp Eye Res; 2016 Aug; 149():100-106. PubMed ID: 27344955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
    Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
    ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.